Member Info for mol42

Just a bit more publicity on our reach announcement

https://www.londonstockexchange.com/news-article/OPTI/slimbiome-study-results/16528317

mol

Co-investigator of the studies Dr Patterson said: “Recent anti-obesity drugs mimicking appetite supressing gut hormones are an important advance in the treatment of obesity, but are not suitable for all. SlimBiome represent an exciting alternative, and we think they increase secretion of your natural gut hormones and this contributes to the suppression of hunger we observe with SlimBiome.”

Just the one comment

Laurentia (Laura) Campbell (ANutr)

Food and nutrition obsessive. Nutritionist and Neuroscientist (mental health, polyphenols, diabetes/obesity, gut microbiota) academic, content writer, food waste warrior & science/healthtech/food/fmcg NPD(ideation-scale)

1mo

Adele Costabile phenomenal news! Please let me know if you ever have any phd opportunities. I would so love to work with your team. Best, Laura

mol

27 June 2024

https://www.linkedin.com/posts/adele-costabile-5557bb106_good-news-to-share-on-the-world-microbiome-activity-7212037222718459904-kRtV

https://x.com/adele759/status/1806302078085546129?lang=en

Adele Costabile

Professor in Clinical Nutrition and Microbiome at Roehampton University

1mo

Study outcome awaiting publication

Good news to share on the World Microbiome Day📣📣📣 Adele Costabile OptiBiotix Health Plc Michael Patterson University of Roehampton

Clinical studies at University of Roehampton reveals SlimBiome benefits in modulating the Microbiome and suggest its use as a natural alternative to anti-obesity drugs.

The latest results from a study conducted by Professor Adele Costabile at the University of Roehampton using Optibitix’s SlimBiome® saw 20 volunteers given 50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes, awaiting publication, suggested SlimBiome® intake had a significant impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness for over two hours after consumption.

These findings on the acute impact of one dose of SlimBiome are consistent with those of a previous first study, also carried out by Professor Adele and her team, published in the Journal of Functional Foods (November 2020) which showed that taking SlimBiome® for four weeks volunteers experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods.

Overall, 90% of volunteers lost weight and all volunteers reported a reduction in waist and hip circumference and lost body fat. In addition, volunteers improved their mood by 26%, suggesting they were losing weight without feeling hungry or craving for food making it more sustainable. This study also showed a significant change in volunteers gut microbiome with a statistically significant increase in microbes associated with a lean body.

These studies suggest that a natural ingredient like SlimBiome®, which was tolerated well in all studies, may offer a natural approach to managing hunger and food cravings to support weight management. Whilst using different mechanisms of action, SlimBiome® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying.

Professor Costabile commented: “Our studies show a mineral enriched prebiotic fibre complex called SlimBiome can reduce hunger and food cravings providing a natural and safe alternative to anti- obesity drugs. Most diets rely on a person’s self-control to restrict calories and, consequently, have a high failure rate. This new approach to weight loss suggests that controlling appetite can help reduce calorie intake and improve the likelihood of success. We are proud Roehampton is at the forefront of this scientific revolution in weight management.”

Only taken 5 years but perhaps prescient

The present invention relates to a non-digestible prebiotic oligosaccharide modified so as to incorporate one or more monosaccharide units thereon and have a higher sweetness value than the unmodified oligosaccharide. Uses and methods of producing the non-digestible prebiotic oligosaccharides are also described.

Patent History

Patent number: 12042506

Type: Grant

Filed: Apr 4, 2019

Date of Patent: Jul 23, 2024

Patent Publication Number: 20210161923

Assignee: OPTIBIOTIX LIMITED

Inventors: Stephen Patrick O'Hara (York), Oswaldo Hernandez (York), Sofia Kolida (York)

Primary Examiner: Dale R Miller

Application Number: 17/044,946

Classifications

Current U.S. Class: Sugars Only (127/30)

International Classification: A61K 31/702 (20060101); A23L 27/30 (20160101); A23L 33/21 (20160101); A61K 9/14 (20060101); A61P 1/00 (20060101);

https://patents.justia.com/patent/12042506

mol

And since year end re vct fund

Events after the Balance Sheet Date

Following the half-year end, the share price of OptiBiotix Health Plc increased by c.97% compared to the

bid price as at 30 June 2024 prior to the publication of this report. As a result of this substantial increase, the

Company was able to realise 645,000 shares at a 1.5x return on original investment cost. The B share pool has a

remaining stake of 1,036,343 shares in OptiBiotix Health Plc

previously

OptiBiotix Health Plc 1,681,343 £336k as at 30 June 2024

I've still to check if any further re eis fund and disposals since 30 june 24

mol

Agreed martinu - i was just in the process of posting the undernoted

i thought i would post Cellan's comments

“Consumer demand for products that seamlessly integrate into their daily routines will continue to drive brands to innovate in the supplement market to combat pill fatigue,” said Cellan Davies, head of marketing at ProBiotix Health.

“For example, nutraceutical formats that offer instant solubility – specifically those that dissolve directly on the tongue – while providing a pleasant mouthfeel, represent an innovative concept that resonates well with consumers.”

Overcoming ODP obstacles

Formulating an ODP demands meticulous consideration of ingredient combinations, particularly regarding taste and mouthfeel.

“This requires significant scientific expertise, especially when incorporating probiotics, which are highly sensitive to moisture and environmental factors like heat,” said ProBiotix Health’s Davies. “Ensuring stability and maintaining product integrity becomes crucial in achieving a high-quality oral dispersible powder. Therefore, dedicated formulation and manufacturing expertise for probiotics are essential,”

For its efforts, ProBiotix has introduced InstaMelt, designed for brands aiming to enhance their health and wellness product offerings with new options. This formulation includes a unique dosing technology that allows for novel delivery methods, coupled with high-quality organoleptic properties.

Davies told FoodBev: “The formulation features our patented probiotic strain, LPLDL, which has been used in multiple studies to demonstrate its efficacy to support cardiometabolic health. Together with

fruity flavours, our solution is a tasty supplement that instantly dissolves on the tongue and has been developed to be best utilised in a stick pack as its main application format.”

“For the technology and processes we use to create our solutions, it should be noted that there it is a delicate operation when working with probiotics due to their live nature, so precise testing, analysis and evaluation are required before a product is routed to market.”

mol

A propos recent discussion here's Cellan amongst others

https://www.foodbev.com/news/tip-of-the-tongue-exploring-the-role-of-oral-disintegration-products

mol

C58 mins

We are the go-to partner for cutting-edge prebiotic ingredients and formulations. Our expert, scientific knowledge, research and innovation delivers superior health solutions, targeting the microbiome for a happier, healthier gut.

Through our innovative formulations, our consistently high-quality products are designed using the latest scientific insights and meet industry regulations.

We work closely with our partners to deliver bespoke prebiotic solutions that align with a brand’s vision.

So, let’s drive health innovation together. Explore our partnership opportunities!

mol (pity that they had probiotic then in the image - nevermind)

Hi martinu

I don't think so as no mention of plant sterols but does mention thiamine (vitamin B1) which is in vh and bp as well

ch below

https://probiotixhealth.com/wp-content/uploads/2023/10/233081-opti-cholbiome-ch-leaflet-update-23-v2-proof.pdf

but i may be wrong

cheers

mol

We await rebranding update then Steen

28 June 2024 RNS re 31 Dec 2023 year end

Highlights

• Distribution agreement with Trans Chem for finished turnkey products in Australia and New

Zealand

• Appointment of Niels Peter Bak as Technical Product Manager

• Launch of CholbiomeCH a dual action bilayer tablet containing phytosterols and LPLDL® to

increase opportunities in the US market

albeit again no mention under yourbiotix thereafter unless i've missed it?

mol

Normally I wouldn't pay much attention to these reports - 23 July 2024

extract

Phytosterols Market Driven By Product Innovations: Launch Of Cholbiome Ch Offers Dual-Action Cholesterol Reduction

Product innovation is the key trend gaining popularity in the phytosterols market. Major companies operating in the phytosterols market are focusing on developing new products and solutions to sustain their position in the market. For instance, in May 2023, ProBiotix Health PLC, a UK-based life sciences company, launched CholBiome CH, an innovative dual-action cholesterol-reducing bi-layer tablet. Lactobacillus plantarum LPLDL and plant sterols/stanols (PSS) are the two active ingredients of the bi-layer tablet, CholBiome CH. These work in combination to support the dual-action cholesterol-reducing formula's goal of lowering both internal and dietary cholesterol levels. The award-winning component LPLDL works on the internal cholesterol to produce enzymes that break down bile salts in this new allergen- and GMO-free innovation, which delivers a dual mode of action. This encourages the liver to eliminate cholesterol from the blood to restore necessary levels and keep the body's bile salt pool in good condition.

https://www.openpr.com/news/3593868/phytosterols-market-size-industry-share-trends-2033

but whilst our mention is very much appreciated and to the fore of the release it did remind me of ch so I then went to our website but couldn't find cholbiome ch redesignated under our yourbiotix rebranding - unless i've missed it

https://probiotixhealth.com/products/

it still can of course be bought on the opti website under cholbiome ch

https://optibiotix.online/collections/cholbiome-range/products/cholbiomech-probiotic-supplement-30-tablets?variant=43616544129239

which is a concern since Steen wants to be his own man and divest pbx from opti

missed this rebranding on website Steen( hope so) or not available under yourbiotix (better be a very good reason not to be -imo) ?

mol

Oops for anyone new

https://seed.com/

re online shop

mol

Following on from recent conversations here

their website has been updated to include a summary of their research - wonderful what a potential sale does - scroll down to pipeline

https://www.seedhealth.com/

i haven't as yet done any further research regarding whether lpldl is incorporated in any of the products in the pipeline but still very encouraged re new 5 year deal - we know lpldl in DS-01 is under clinical development by Seed Health and currently in Phase II for Irritable Bowel Syndrome but isn't mentioned in pipeline

unless i've missed it

mol

Eventually!

https://find-and-update.company-information.service.gov.uk/company/11330264/filing-history

does he read this board?

someone must as before get a grip nothing was happening - i'm going to take the credit anyway lol

bw all

mol

Appointments

https://www.optibiotix-ir.com/content/news/archive/2022/010322

apart from rene kamminga you might have wondered about Karl

Karl Burkitt has a rich career in which he developed and led the marketing and business development function in various branded and ingredient businesses, such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB Mauri. Karl will lead our marketing function, on a part time basis, and work closely with the pro- and prebiotic commercial divisions on developing ingredient and consumer sales.

The above appointments expand the capabilities of our management team in line with our commercial strategy, which is to further expand ingredient sales, particularly in the large North American market, whilst developing our final product sales containing our unique ingredients.

René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12 months we have established the credibility and brand awareness of our science-based ingredients SlimBiome®, OptiBiome, LeanBiome and LPLDL® ingredients, significantly growing sales to a wider number of reputable global brands in multiple markets. These appointments are a further investment to accelerate the growth of the Company and to broaden and deepen our income streams with a particular focus on North America and E-Commerce."

well here's Karl's take

Interim Global Marketing Director

OptiBiotix Health Plc

Jan 2022 - Nov 2022 11 months

London UK

Part-Time interim director role leading corporate and brand marketing/comms for a business focused on microbiome based consumer health and wellness solutions. Led concept development and product launches in the UK and internationally, for B2C and B2B channels for weight management, heart health and sports nutrition categories.

we still have zak apparently as well shiraz ( the effect)

just a bit of info

and of course through it all we have had young Tom - albeit he has given up his co-business development role and previously head of supply chain at PBX recently

https://uk.linkedin.com/in/tom-o-hara-6a8686184

mol

Https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/tablets-and-medication/glp-1

opportunity

albeit NICE is a difficult hurdle to overcome but if we go down perhaps the right route....... (ie not diabetes)

mind we did have an MP on board until recently - though perhaps either he wasn't advised by us on the opportunity because we didn't appreciate same at time ( or i think we thought too much hassle) or he wasn't up to it

i suspect the former unfortunately

mol

Here's a post from Zachary

Zachary Sniderman

Director of Business Development, North America

3w (ago ie June 2024)

This week’s ISSN conference exceeded all expectations. Thank you to Sidney Abou Sawan, PhD, MSc for recommending that we present OptiBiotix Health Plc research.

Brands, practitioners, and researchers had fantastic questions about Professor Adele Costabile's LeanBiome human intervention studies. Specifically, LeanBiome’s ability to curb cravings, suppress hunger, and foster a "lean" microbiome—qualities highly sought after in a market increasingly focused on natural satiety solutions, especially with the emergence of GLP-1 RA medication.

Not only will I leave the conference with new potential partners, but I’m also taking great nutrition research for my daily workout. Thanks to the entire ISSN Staff!

and a thank you from adele

Professor in Clinical Nutrition and Microbiome at Roehampton University

3w

Thank you Zachary Sniderman and I hope we meet soon!

mind that's the only reaction

https://www.linkedin.com/posts/zacharysniderman_prebiotics-microbiome-guthealth-activity-7209585915826966529-eWCR

mol

And of course opportunity - never been a better time methinks

can we avail of same?

we will see in the not too distant future

mind still not on boots online as of today

mol

A number of dm articles prior and post midas recommendation

https://www.dailymail.co.uk/health/article-13556355/weight-loss-ozempic-quit-drug.html

https://www.dailymail.co.uk/health/article-13620101/ozempic-quitting-patients-weight-loss-effects.html

albeit today limited read online to date

https://www.dailymail.co.uk/health/article-13631287/weight-loss-jab-beach-body-ready-dose-realised-terrible-mistake.html

just a bit of info

mol

There are better ways to achieve the same outcome Mark if that is what is wanted

Get a grip

https://find-and-update.company-information.service.gov.uk/company/11330264/filing-history

Mark was appointed secretary of plc on 9 april 2024

he may be cfo of plc but not a director of same

mol